Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Coya Therapeutics (NASDAQ:COYA) released its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07, FiscalAI reports. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative return on equity of 62.69% and a negative net margin of 266.10%.

Coya Therapeutics Stock Performance

Shares of Coya Therapeutics stock traded up $0.34 during trading hours on Thursday, hitting $4.88. The company’s stock had a trading volume of 78,052 shares, compared to its average volume of 185,969. The business has a 50 day moving average price of $4.37 and a two-hundred day moving average price of $5.05. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75. The company has a market cap of $114.48 million, a PE ratio of -4.24 and a beta of 0.55.

Hedge Funds Weigh In On Coya Therapeutics

Large investors have recently made changes to their positions in the business. Trexquant Investment LP purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth about $145,000. Jump Financial LLC purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth about $198,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth about $200,000. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth about $196,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Coya Therapeutics by 58.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 31,429 shares of the company’s stock worth $182,000 after buying an additional 11,648 shares in the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on COYA shares. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, March 23rd. D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Friday, April 10th. Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. Finally, Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.